Amgen Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Amgen Inc. stock analysis AMGN overview
Somewhat Bullish +50

Is Amgen (AMGN) One of the Most Profitable Value Stocks to Buy Right Now? - Yahoo Finance

📈 Amgen is identified as one of the 7 Most Profitable Value Stocks to Buy Right Now.

💉 The company announced positive Phase 3 trial results for TEPEZZA, a treatment for Thyroid Eye Disease.

🩺 A subcutaneous formulation was tested using an on-body injector administered every two weeks.

📊 77% of participants achieved significant improvement in eye bulging compared to ~20% in the placebo group.

🔍 Secondary endpoints showed clinically meaningful improvements, including a 3.17 mm mean proptosis reduction at week 24.

😊 Enhanced quality-of-life scores and positive responses in double vision were also observed.

🔄 The new subcutaneous option aims to replace IV infusions for over 25,000 patients seeking more convenient access.

⚠️ Safety profiles remained consistent with the established IV version, with only mild-to-moderate injection site reactions noted.

💼 Amgen is a drug manufacturer headquartered in California, founded in 1980 and operates through pharmaceutical distributors.

🧠 The article suggests AI stocks may offer greater upside potential than AMGN despite its profitable status.

🗣️ Readers are directed to free reports on short-term AI stocks benefiting from tariff policies.

🔗 Additional reading includes a list of 33 stocks expected to double in three years and Cathie Wood's 2026 portfolio.

Bullish Signals
  • On April 6, Amgen announced positive topline results from a Phase 3 trial evaluating a subcutaneous formulation of TEPEZZA for patients with moderate-to-severe active Thyroid Eye Disease.
  • The trial successfully met its primary endpoint, with 77% of participants achieving a significant proptosis response compared to only approximately 20% in the placebo group.
  • Secondary endpoints showed clinically meaningful improvements, including a mean proptosis reduction of 3.17 mm at week 24 and enhanced quality-of-life scores.
  • The subcutaneous formulation could evolve the standard of care by offering a more convenient and accessible delivery method for the 25,000+ patients who have historically relied on IV infusions.
  • The safety profile for the subcutaneous administration was generally consistent with the established IV profile, with only mild-to-moderate injection site reactions reported.
Risk Factors
  • The article does not provide positive details that may mislead readers about the stock's potential.
  • Amgen is suggested as having less upside potential compared to AI stocks, which could indicate concerns about its growth trajectory or competitive positioning in emerging sectors.
Full Analysis
Amgen Inc. (NASDAQ:AMGN) has been highlighted as one of seven of the most profitable value stocks to consider buying, following significant positive clinical data released on April 6. The biotechnology company announced successful topline results from a Phase 3 trial evaluating a subcutaneous formulation of its drug TEPEZZA for patients with moderate-to-severe active Thyroid Eye Disease. The study utilized an on-body injector to administer the medication every two weeks, demonstrating efficacy comparable to the currently approved intravenous/IV version. The trial achieved its primary endpoint, with 77% of participants experiencing a significant proptosis response, representing a substantial reduction in eye bulging compared to approximately 20% in the placebo group. Secondary endpoints also indicated clinically meaningful improvements, including a mean proptosis reduction of 3.17 mm at week 24 and enhanced quality-of-life scores. The subcutaneous option is designed to offer a more convenient delivery method for over 25,000 patients who have historically relied on IV infusions, while maintaining a safety profile consistent with the established intravenous version, aside from some mild-to-moderate injection site reactions. Beyond the clinical updates, Amgen operates as a drug manufacturer delivering human therapeutics through pharmaceutical wholesale distributors and is headquartered in California, having been founded in 1980. The article concludes with a perspective suggesting that while Amgen presents investment potential, certain AI stocks are viewed by the author as offering greater upside potential with less downside risk, specifically those benefiting from tariffs and onshoring trends. Readers are directed to further reports on short-term AI stock picks and Cathie Wood's 2026 portfolio recommendations.